Long term assessment of localized functional and anatomical outcomes after multiple anti-VEGF treatment in AMD
Feigl, Beatrix, Greaves, Amanda, Aralar, Albert, & Brown, Brian (2007) Long term assessment of localized functional and anatomical outcomes after multiple anti-VEGF treatment in AMD. In 39th Annual Scientific Congress of The Royal Australian and New Zealand College of Ophthalmologists, 24-28 November, Perth, Australia.
Purpose: To investigate the effect of multiple treatments with ranibizumab or bevacizumab in neovascular age-related macular degeneration (AMD) using electrophysiological and anatomical measures. Methods: We monitored five AMD patients before and after intravitreal treatment with ranibizumab (0.5mg) or bevacizumab (1.25mg) over 8-11 months (mean 10 ±1.2 months). Three patients received ranibizumab and two patients received bevacizumab. Central and peripheral neuroretinal function was assessed using multifocal electroretinography and optical coherence tomography was used to measure central retinal thickness. Visual acuity and contrast sensitivity were assessed with Bailey-Lovie and Pelli-Robson charts. Results: Patients in the ranibizumab group received 5, 5 and 6 treatments and patients in the bevacizumab group received 2 treatments over a mean period of 10 months. In both groups mean peripheral neuroretinal activity transiently decreased between the treatments but not significantly whereas mean central function improved or remained stable compared to pretreatment levels after the 10 months. Central retinal thickness decreased by 163 (±14) μm and by 110 (±16) μm in the ranibizumab and bevacizumab treated group, respectively. Visual acuity improved (>3 lines) in one patients (ranibizumab group) and remained stable in four patients. Contrast sensitivity improved (>6 letters) in one patient (bevacizumab group) and remained stable in four patients. Conclusion: Both groups show improved anatomical and central improved/stable functional outcomes compared to pretreatment after long term follow up, even though the ranibizumab group received more than twice the number of treatments than the bevacizumab group.
Impact and interest:
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Conference Paper|
|Additional Information:||For more information, please refer to the society’s website (see hypertext link) or contact the author.|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > OPTOMETRY AND OPHTHALMOLOGY (111300)|
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > OPTOMETRY AND OPHTHALMOLOGY (111300) > Vision Science (111303)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > OPTOMETRY AND OPHTHALMOLOGY (111300) > Optical Technology (111302)
|Divisions:||Current > Research Centres > Centre for Health Research|
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2007 (please consult author)|
|Deposited On:||20 Feb 2008|
|Last Modified:||20 May 2010 02:33|
Repository Staff Only: item control page